Follow the HLB테라퓨틱스 share price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, HLB테라퓨틱스 has logged 61 insider filings. Market capitalisation: €185.6bn. The latest transaction was reported on 10 June 2026 (Purchase). Among the most active insiders: HLB. All data is free.
57
Insider Decl.
n/a
Thresholds
€49,275
43 ops.
Buy Volume
n/a
1 ops.
Sell Volume
16Σ signal
Buys €49,275n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,357 of 29,062 companies
17.0
score / 100
Value
19
Quality
15
FCF yld-9.8%
Earn yld-5.0%
EV/EBITDA·
ROE-11%
Gross mgn15%
Net mgn-13%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
HLB테라퓨틱스 es una empresa que opera en el sector de la salud y farmacéutico, cotizada en el mercado XKRX. Se enfoca en el desarrollo de tratamientos y soluciones terapéuticas innovadoras.